1. Scrip
  2. >>Drug Pricing

How Many Pricing Hearings Add Up To Action On Pricing Transparency?

 
• By Cathy Kelly

Mylan’s discussion of how the drug supply chain absorbs pricing for EpiPen raised more questions than it answered during a House Oversight Committee hearing

PharmacyReceipt-Dollars-PillBottles_1200x675

Mylan Pharmaceuticals Inc.may be regretting its tactic of trying to deflect criticism over big EpiPen price increases by arguing that more than half of the drug’s $608 list price is being absorbed by the drug supply chain, which is leading to calls for more transparency, particularly around pharmacy benefit managers.

The argument raised many more questions than Mylan CEO Heather Bresch was prepared to answer at a House Oversight and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.

Big Patent Blow For Roche’s Evrysdi In India But It May Not Be Over Yet

 
• By Anju Ghangurde

Roche, which faced a high stakes patent setback for Evrysdi in India, appears to have appealed against a lower court’s ruling, which went decisively Natco’s way but also included distinct 'reservations' by the judges.

US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions

 
• By Sarah Karlin-Smith

Marty Makary's role in helping negotiation the Trump Administration's second "most favored nations" drug pricing deal is raising concerns as the Trump team has suggested it would use drug pricing as a lever to impact FDA approval status or speed of drug reviews.

‘Building The Plane While Flying It’: Cell And Gene Therapy Makers Prepare For MFN Pricing, Tariffs

 
• By Mandy Jackson

It remains to be seen whether the Trump administration’s most favored nation drug pricing policy will trickle down from big pharma to small biotech, but executives said at ARM’s Cell and Gene Meeting on the Mesa that they are preparing strategies now to manage the future.

More from Scrip

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.